Adolore BioTherapeutics Unveils Strategy for Non-Opioid Analgesic Gene Therapies

Adolore BioTherapeutics, a biotechnology company, has announced significant progress in its pipeline for opioid-free gene therapy treatments targeting chronic pain. The company’s development program for osteoarthritis (OA) knee pain is fully funded through initial clinical studies by a NIH/NINDS HEAL program grant.

Adolore is advancing two preclinical programs: ADB-101 for erythromelalgia and ADB-102 for knee OA. The company's approach utilizes CA8* gene therapy, a novel non-opioid, analgesic protein, and a bio-engineered HSV-derived vector for efficient delivery to sensory neurons.

Plans to present data at scientific congresses and publish in leading journals are in place for 2024. The company is scaling up its manufacturing process and expects to produce its initial GMP batch by 2025. Recent achievements include the issuance of a U.S. patent for CA8* gene therapy.

Financially, Adolore has raised $2.5 million in convertible debt, projected to sustain operations through mid-2026.